

Special Issue

Hallmark Properties and Behind-the-Scenes Role of Non-coding RNAs in Gastrointestinal Cancers' Onset, Progression and Metastasis

Message from the Guest Editors

GI cancers encompass a heterogeneous group of neoplastic diseases sharing some common risk factors but differing in etiology, prognosis and clinical management across the various tumor types. The main malignant conditions of the GI tract involve, in order, colorectum, stomach, liver, esophagus and pancreas. Understanding the molecular basis of GI cancers is a crucial point for the development of new diagnostic and therapeutic strategies. Extensive genomic studies revealed recurrent mutations or copy number variations frequently located in ncDNA regions, suggesting their impact on the emerging complexities underlying the development and progression of GI neoplasms. Non-coding genomic regions cover 95% of the whole DNA and are, for the most part, transcribed into functional ncRNAs, including miRNAs, endogenous small interfering RNAs (endo-siRNAs), snoRNAs, circRNA, and lncRNAs, which represent the largest class of non-coding transcripts. This Special Issue will report the most recent advances in understanding ncRNAs' role in GI neoplasms' tumorigenesis and progression, focusing on their application as tumor markers and therapeutic agents.

Guest Editors

Dr. Gabriella Misso

Dr. Alessia Maria Cossu

Dr. Michela Falco

Deadline for manuscript submissions

closed (31 December 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/119055

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)